Experienced in Angiosarcoma of the Liver

Nathalie Carrie-Ganne

CHU Caen
Caen, FR 
Experienced in Angiosarcoma of the Liver
CHU Caen
Caen, FR 
OverviewLocationsClinical Research

Overview

Nathalie Carrie-Ganne practices in Caen, France. Ms. Carrie-Ganne is rated as an Experienced expert by MediFind in the treatment of Angiosarcoma of the Liver. Her top areas of expertise are Liver Cancer, Alcoholic Cirrhosis, Cirrhosis, Liver Transplant, and Cardiac Ablation.

Her clinical research consists of co-authoring 148 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Angiosarcoma of the Liver.

Gender
Female

Locations

CHU Caen
Caen, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Impact of COVID-19 Infection in Patients With Hepatocellular Carcinoma: An Ambispective Study Nestled in the CHIEF Cohort
Impact of COVID-19 Infection in Patients With Hepatocellular Carcinoma: An Ambispective Study Nestled in the CHIEF Cohort
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2024
Intervention Type: Diagnostic test
Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients With Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2)
Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients With Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2)
Enrollment Status: Unknown
Publish Date: August 25, 2023
Intervention Type: Drug
Study Drug: Peginterferon Lambda-1a
Study Phase: Phase 3
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: August 02, 2022
Intervention Type: Drug
Study Phase: Phase 3
Feasibility and Performances of Spleen Stiffness Measurement as Surrogate Marker for Oesophageal Varices in Cirrhotic Patients.
Feasibility and Performances of Spleen Stiffness Measurement as Surrogate Marker for Oesophageal Varices in Cirrhotic Patients.
Enrollment Status: Completed
Publish Date: October 10, 2018
Intervention Type: Device
Study Phase: Not Applicable
View 3 Less Clinical Trials

148 Total Publications

Advocating for scalable etiology-agnostic HCC risk models for personalized HCC surveillance.
Advocating for scalable etiology-agnostic HCC risk models for personalized HCC surveillance.
Journal: Journal of hepatology
Published: August 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Carrie-Ganne's expertise for a condition
ConditionClose
View All 33 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile